{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Congdon EE"],"funding":["NIA NIH HHS","NINDS NIH HHS"],"pagination":["715-736"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10965012"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(12)"],"pubmed_abstract":["Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However, trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting agents in clinical trials are immunotherapies. In this Review, we provide an update on the results from the initial immunotherapy trials and an overview of new therapeutic candidates that are in clinical development, as well as considering future directions for tau-targeting therapies."],"journal":["Nature reviews. Neurology"],"pubmed_title":["Tau-targeting therapies for Alzheimer disease: current status and future directions."],"pmcid":["PMC10965012"],"funding_grant_id":["R01 AG032611","R01 NS077239","R21 AG069475","T32 AG052909","RF1 NS120488","R01 NS120488"],"pubmed_authors":["Jiang Y","Ji C","Tetlow AM","Sigurdsson EM","Congdon EE"],"additional_accession":[]},"is_claimable":false,"name":"Tau-targeting therapies for Alzheimer disease: current status and future directions.","description":"Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However, trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting agents in clinical trials are immunotherapies. In this Review, we provide an update on the results from the initial immunotherapy trials and an overview of new therapeutic candidates that are in clinical development, as well as considering future directions for tau-targeting therapies.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-03T01:04:48.487Z","creation":"2025-04-04T01:58:26.991Z"},"accession":"S-EPMC10965012","cross_references":{"pubmed":["37875627"],"doi":["10.1038/s41582-023-00883-2"]}}